| 王 宏,夏永寿,加 静,张 燕,王 瑛.沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察[J].,2018,(23):4474-4477 |
| 沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察 |
| Therapeutic Effect of Thalidomide Combined with Gefitinib on Non-small Cell Lung Cancer |
| 投稿时间：2018-04-28 修订日期：2018-05-23 |
| DOI：10.13241/j.cnki.pmb.2018.23.017 |
| 中文关键词: 非小细胞肺癌 沙利度胺 吉非替尼 |
| 英文关键词: Non-small cell lung cancer Thalidomide Gefitinib |
| 基金项目:陕西省教育厅科学研究计划项目（2013JK0799） |
|
| 摘要点击次数: 528 |
| 全文下载次数: 239 |
| 中文摘要: |
| 摘要 目的：探讨沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果。方法：选取2014年1月-2016年12月我院收治的非小细胞肺癌患者79例，按照治疗方法的不同分为对照组40例、观察组39例。对照组进行常规非小细胞肺癌治疗，观察组在手术前给予沙利度胺联合吉非替尼靶向治疗后行常规治疗。比较两组临床疗效，6个月、1年生存率，并记录观察组患者不良反应的发生情况。结果：观察组化疗的化疗缓解率(71.79 %)显著高于对照组(52.50 %)(P<0.05)。观察组患者在治疗期间出现了不同程度的白细胞减少、、恶心呕吐、关节痛、脱发、肝功能损伤等不良反应，患者对以上症状均可耐受，给予对症治疗后均自行缓解。观察组患者6个月、1年生存率均显著高于对照组(P<0.05)。结论：沙利度胺联合吉非替尼靶向治疗NSCLC患者的疗效较好，能显著提高患者生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of thalidomide combined with gefitinib in the treatment of non-small cell lung cancer. Methods: Selected 79 NSCLC patients admitted to our hospital from January 2014 to December 2016. All patients were divided into control group (n=40) and observation group (n=39) by treatment methods. The control group received NSCLC routine treatment. The observation group was given thalidomide combined with gefitinib targeted therapy before surgery, then received routine treatment. The clinical efficacy, 6 months and 1 year survival rates between two groups were compared. The incidence of adverse reactions in the obser- vation group was recorded. Results: The chemotherapy remission rate in the observation group (71.79 %) was significantly higher than that in the control group (52.50 %) (P<0.05). The patients in the observation group experienced various adverse reactions such as neu- tropenia, nausea and vomiting, joint pain, hair loss, and liver function impairment during the treatment period. Patients can tolerate the above symptoms, and they all relieve themselves after symptomatic treatment. The 6-month and 1-year survival rates in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Thalidomide combined with gefitinib is effective in the treatment of NSCLC patients and can significantly improve the survival rate of patients. It is worth further study. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
